Personal information

No personal information available

Activities

Collapse all

Employment (3)

Yale Center for Clinical Investigation, Yale School of Medicine: New Haven, CT, US

2023 to present | Postdoctoral Associate (Neurosurgery)
Employment
Source: Self-asserted source
Mircea Tesileanu

European Medicines Agency: Amsterdam, NL

2022-06 to 2023-06 | Seconded National Expert (Hematology and Oncology)
Employment
Source: Self-asserted source
Mircea Tesileanu

Erasmus MC: Rotterdam, Zuid-Holland, NL

2018 to 2023 | PhD candidate (Neuro-Oncology)
Employment
Source: Self-asserted source
Mircea Tesileanu

Works (46)

Queries Raised During Oncology Business Pipeline Meetings at the European Medicines Agency: A 5‐Year Retrospective Analysis

Clinical Pharmacology & Therapeutics
2023-11 | Journal article
DOI: 10.1002/cpt.3015
Contributors: C. Mircea S. Tesileanu; Francesco Pignatti; Enrico Tognana; Anthony Humphreys
Source: check_circle
Crossref

The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors

The Oncologist
2023-07-05 | Journal article
DOI: 10.1093/oncolo/oyad119
Contributors: C Mircea S Tesileanu; Sotirios Michaleas; Rocio Gonzalo Ruiz; Segundo Mariz; Babs O Fabriek; Paula B van Hennik; Jutta Dedorath; Bruna Dekic; Christoph Unkrig; Andreas Brandt et al.
Source: check_circle
Crossref

Glioblastoma lacking necrosis or vascular proliferations: different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation

2023-06-19 | Other
DOI: 10.1093/noajnl/vdad075
Contributors: Maarten Wijnenga; Pim J. French; Martin J. van den Bent; Mircea Mircea S. Tesileanu; Linda Dirven
Source: check_circle
Crossref

IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas

Neuro-Oncology
2023-04-06 | Journal article
DOI: 10.1093/neuonc/noac197
Contributors: Mark P van Opijnen; C Mircea S Tesileanu; Linda Dirven; Pim B van der Meer; Maarten M J Wijnenga; Arnaud J P E Vincent; Marike L D Broekman; Hendrikus J Dubbink; Johan M Kros; Sjoerd G van Duinen et al.
Source: check_circle
Crossref

Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532437
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532437.v1
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Data from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532518.v1
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Data from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532518
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487019.v1
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487019
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Data from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487442
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Data from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487442.v1
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487016.v1
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487007
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487007.v1
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487016
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487013
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487013.v1
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487010
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487010.v1
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487004
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487004.v1
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487001.v1
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487001
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486998.v1
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486998
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487439.v1
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487433
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487430
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487427
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487427.v1
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487424
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487424.v1
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487439
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487421
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487421.v1
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487433.v1
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487430.v1
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review

European Journal of Cancer
2022-11 | Journal article
DOI: 10.1016/j.ejca.2022.08.016
Contributors: C. Mircea S. Tesileanu; Wies R. Vallentgoed; Pim J. French; Martin J. van den Bent
Source: check_circle
Crossref

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Clinical Cancer Research
2022-06-13 | Journal article
DOI: 10.1158/1078-0432.CCR-21-4283
Contributors: C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason et al.
Source: check_circle
Crossref

Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Clinical Cancer Research
2022-06-01 | Journal article
DOI: 10.1158/1078-0432.CCR-21-3725
Contributors: Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland et al.
Source: check_circle
Crossref

MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas

Neuro-Oncology
2022-04-01 | Journal article
DOI: 10.1093/neuonc/noac014
Contributors: C Mircea S Tesileanu; Thierry Gorlia; Vassilis Golfinopoulos; Pim J French; Martin J van den Bent
Source: check_circle
Crossref

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

Neuro-Oncology
2021-09-01 | Journal article
DOI: 10.1093/neuonc/noab088
Contributors: C Mircea S Tesileanu; Martin J van den Bent; Marc Sanson; Wolfgang Wick; Alba A Brandes; Paul M Clement; Sara C Erridge; Michael A Vogelbaum; Anna K Nowak; Jean F Baurain et al.
Source: check_circle
Crossref

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.

The Lancet. Oncology
2021-05-14 | Journal article
DOI: 10.1016/s1470-2045(21)00090-5
PMID: 34000245
Source: Self-asserted source
Mircea Tesileanu

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.

Acta neuropathologica
2021-03-19 | Journal article
DOI: 10.1007/s00401-021-02291-6
PMID: 33740099
PMC: PMC8113211
Source: Self-asserted source
Mircea Tesileanu

Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria

Neuro-Oncology
2020-04-15 | Journal article
DOI: 10.1093/neuonc/noz200
Contributors: C Mircea S Tesileanu; Linda Dirven; Maarten M J Wijnenga; Johan A F Koekkoek; Arnaud J P E Vincent; Hendrikus J Dubbink; Peggy N Atmodimedjo; Johan M Kros; Sjoerd G van Duinen; Marion Smits et al.
Source: check_circle
Crossref

Peer review (1 review for 1 publication/grant)

Review activity for Neuro-oncology advances. (1)
How many people are using ORCID?